Compare CHMG & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CHMG | GLSI |
|---|---|---|
| Founded | 1833 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 322.1M | 327.2M |
| IPO Year | 1995 | 2020 |
| Metric | CHMG | GLSI |
|---|---|---|
| Price | $66.20 | $24.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $57.00 | $50.00 |
| AVG Volume (30 Days) | 10.0K | ★ 106.0K |
| Earning Date | 04-17-2026 | 05-19-2026 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $37.32 | N/A |
| Revenue Next Year | $9.13 | N/A |
| P/E Ratio | $35.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $45.55 | $7.78 |
| 52 Week High | $70.83 | $34.10 |
| Indicator | CHMG | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 57.42 | 50.95 |
| Support Level | $50.67 | $23.32 |
| Resistance Level | $70.41 | $30.08 |
| Average True Range (ATR) | 2.52 | 1.55 |
| MACD | -0.24 | 0.05 |
| Stochastic Oscillator | 25.30 | 62.53 |
Chemung Financial Corp is a bank holding firm. Through its subsidiaries, the company provides various financial services, including demand, savings, and time deposits, commercial, residential, and consumer loans, letters of credit, wealth management services, employee benefit plans, insurance products, mutual funds, and brokerage services, among others. The company's reportable segments are Core Banking, Wealth Management (WMG) services, and Holding company and CFS. Maximum revenue is generated from the Core Banking segment, which derives revenue by attracting deposits from the general public and using such funds to originate different types of loans, and to invest in securities. The Wealth Management (WMG) services segment provides trust and investment advisory services to clients.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.